-transparent.png){kind=logo}
The potential utility of intermittent regimens of oral acyclovir for suppression of recurrent genital herpes depends on how long the suppressive effect of the drug persists during pauses in treatment. To study this question, we admitted 38 patients in a double-blind controlled trial comparing the results of daily acyclovir treatment (200 mg t.i.d.) with treatment on weekend days only (400 mg t.i.d. on Saturday and Sunday) for suppression of recurrent genital herpes. Of the 35 patients completing the study, significantly more failures occurred in the weekend group (13/17) than in the daily group (3/18, P less than 0.001). Failures on the weekend regimen were more frequent as the week progressed (P = 0.005). The findings suggest a short-term persistence of suppression by acyclovir and hence that intermittent regimens with more closely spaced periods of treatment may be more effective than the regimen we studied. Most virus isolates studied, including all of those isolated from the patients during treatment, were sensitive to acyclovir.
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
January 1985,
Acta dermato-venereologica,
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
January 1985,
Scandinavian journal of infectious diseases. Supplementum,
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
August 1985,
The Journal of antimicrobial chemotherapy,
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
November 1985,
Zeitschrift fur Hautkrankheiten,
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
August 1988,
The American journal of medicine,
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
June 1984,
The New England journal of medicine,
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
October 1991,
The Journal of infectious diseases,
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
July 1984,
Lancet (London, England),
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
January 1987,
Scandinavian journal of infectious diseases,
S E Straus, and
M Seidlin, and
H E Takiff, and
J F Rooney, and
S N Lehrman, and
S Bachrach, and
J M Felser, and
J J Di Giovanna, and
G J Grimes, and
H Krakauer
December 1985,
The British journal of dermatology,
